Holdings
Cormorant Asset Management, LP
As of Sep 30, 2026, Cormorant Asset Management, LP reported 54 positions worth US$1.42B. Largest: Parabilis Medicines, Inc., Praxis Precision Medicines, Inc. and Rapport Therapeutics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Parabilis Medicines, Inc. | 4.62M | US$149M | no change | Sep 30, 2026 |
| Praxis Precision Medicines, Inc. | 500K | US$146M | −140K | Sep 30, 2026 |
| Rapport Therapeutics, Inc. | 2.46M | US$82.6M | −200K | Sep 30, 2026 |
| Edgewise Therapeutics, Inc. | 1.86M | US$75.5M | −650K | Sep 30, 2026 |
| BridgeBio Oncology Therapeutics, Inc. | 17.9M | US$73.3M | no change | Sep 30, 2026 |
| Erasca, Inc. | 5M | US$73.3M | −1M | Sep 30, 2026 |
| BlossomHill Therapeutics, Inc. | 3.61M | US$67.4M | new | Sep 30, 2026 |
| Adlai Nortye Group Ltd. | 3.98M | US$63.7M | new | Sep 30, 2026 |
| Dianthus Therapeutics, Inc. | 500K | US$44M | −250K | Sep 30, 2026 |
| Abivax SA | 425K | US$42.1M | −250K | Sep 30, 2026 |